SynthesisFrontiers in immunology2026
Efficacy, safety, and PD-L1-defined outcomes of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Chang Ma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.